CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Galdakano, Spain

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

    Phase

    3

    Span

    60 weeks

    Sponsor

    Arthrosi Therapeutics

    Honolulu, Hawaii

    Recruiting

  • A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

    Phase

    1/2

    Span

    45 weeks

    Sponsor

    BioNTech SE

    Honolulu, Hawaii

    Recruiting

    Healthy Volunteers

  • A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

    The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite of > 50% decline in eGFR, kidney failure, or CV death, in individuals with CKD and HTN. This study consists of a 4-week dapagliflozin Run-in Period for participants untreated with SGLT2i at screening, and a double-blinded period where participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin. Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of primary endpoint events is predicted to have occurred ie, the PACD. All randomised participants including any participants who have prematurely discontinued study intervention will be scheduled for a SCV within a few weeks of the PACD. This period can be extended by the Sponsor. In case of premature discontinuation of blinded study intervention, participants will continue in the study and receive dapagliflozin 10 mg, unless the participant meets dapagliflozin specific discontinuation criteria. If study intervention is temporarily or permanently discontinued, the participant should remain in the study, and it is important that the scheduled study visits (including the PTDV for participants with permanent discontinuation of study intervention) and data collection continue according to the study protocol until the SCV.

    Phase

    3

    Span

    268 weeks

    Sponsor

    AstraZeneca

    Honolulu, Hawaii

    Recruiting

  • A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

    Phase

    2

    Span

    58 weeks

    Sponsor

    Pfizer

    Honolulu, Hawaii

    Recruiting

  • A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

    Phase

    2

    Span

    119 weeks

    Sponsor

    Eli Lilly and Company

    Honolulu, Hawaii

    Recruiting

  • A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

    Phase

    3

    Span

    140 weeks

    Sponsor

    ModernaTX, Inc.

    Honolulu, Hawaii

    Recruiting

    Healthy Volunteers

  • A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

    Part A Healthy Volunteers Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity

    Phase

    2

    Span

    141 weeks

    Sponsor

    Regeneron Pharmaceuticals

    Honolulu, Hawaii

    Recruiting

    Healthy Volunteers

  • A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

    Phase

    3

    Span

    251 weeks

    Sponsor

    Madrigal Pharmaceuticals, Inc.

    Honolulu, Hawaii

    Recruiting

  • A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

    Phase

    3

    Span

    127 weeks

    Sponsor

    Eli Lilly and Company

    Honolulu, Hawaii

    Recruiting

  • A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Phase

    3

    Span

    110 weeks

    Sponsor

    Eli Lilly and Company

    Honolulu, Hawaii

    Recruiting

1-10 of 135
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information